

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014

DESPATCHED ON 26TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B62, B64; Cw9, Cw8; DR15, DR13; DQ6, -

Summary of Results					Summary of Results				
Total tested	21	21	20	21	17	17	16	16	
Positive	0	0	14	0	0	0	12	0	
Negative	21	21	6	21	17	17	4	16	
Not Tested	2	2	2	2	2	2	2	2	
% Positive	0.0%	0.0%	70.0%	0.0%	0.0%	0.0%	75.0%	0.0%	
% Negative	100.0%	100.0%	30.0%	100.0%	100.0%	100.0%	25.0%	100.0%	
<b>Consensus</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Positive</b>	<b>Negative</b>	
HLA Antibody (Defined By CDC)	DQ3	A32,B44,DR7	Bw6	B7,DR2					

  

Lab No.	Without DTT				With DTT ( Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	The blood was lysed - No cells recovered
11	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
12	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
14	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
15	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
23	Negative	Negative	Positive	Negative					
24	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
25	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
28	Negative	Negative	Negative	Negative	Negative	Negative	Unsatisfactory	Unsatisfactory	
34	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
35	Negative	Negative	Equivocal	Negative					
38	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
39	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
41	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
42	Negative	Negative	Weak Positive	Negative	Negative	Negative	Weak Positive	Negative	
45	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
48	NT	NT	NT	NT	NT	NT	NT	NT	
51	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
54	Negative	Negative	Positive	Negative					
58	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
62	Negative	Negative	Negative	Negative					

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014

DESPATCHED ON 26TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
9	0	0	4	0	0	0	4	0	17-Sep	18-Sep	Yes	Yes	90	Cedarlane	30	30	AO/PI	
11			2				2		18-Sep	19-Sep		Yes	90	Cedarlane	45	90	Fluoroquencher	
12	5%	5%	60%	5%	5%	5%	30%	5%	17-Sep	17-Sep	Yes	No	95	Cedarlane	30	90	EB/AO	
14	0	0	4	0	0	0	6	0	17-Sep	17-Sep		Yes	90	Cedarlane	60	120	EB/AO	
15			4				4		17-Sep	17-Sep	Yes	Yes	90	TCS Biosciences	60	60	EB/AO	
19	NT	NT	NT	NT	NT	NT	NT	NT	17-Sep	18-Sep	NT	NT	NT	NT	NT	NT	NT	
20	1	1	1	1	1	1	1	1	17-Sep	18-Sep	Yes	No	90	Cedarlane	30	120	EB/AO	
23	1	1	8	1					17-Sep	17-Sep		Yes	90	Cedarlane	40	40	EB/AO	
24	20%	20%	90%	10%	20%	20%	100%	20%	17-Sep	18-Sep		Yes	90	Cedarlane	45	90	EB/AO	
25	1	1	8	1	1	1	8	1	18-Sep	18-Sep		Yes	99	Cedarlane	45	60	Fluoroquencher	
28	1	1	1	1	1	1			17-Sep	17-Sep		Yes	90	Cedarlane	30	45	EB/AO	
34	1	1	1	1	1	1	1	1	17-Sep	17-Sep		Yes	100	Cedarlane	30	90	EB/AO	
35	1	1	1	1					17-Sep	18-Sep	Yes	No	90	Cedarlane	60	120	Fluoroquencher	
38	1	1	1	1	1	1	1	1	17-Sep	17-Sep	Yes	Yes	95	95	Cedarlane	60	60	EB/AO
39			2				2		17-Sep	17-Sep	Yes	No	99	Cedarlane	45	90	EB/AO	
41	2%	2%	2%	2%	5%	5%	5%	5%	17-Sep	17-Sep	Yes	Yes	98	98	Cedarlane	60	60	EB/AO
42			20%				20%		17-Sep	18-Sep	Yes	No	95	TCS Biosciences	60	120	EB/AO	
45	1	1	8	1	1	1	6	1	17-Sep	17-Sep		Yes	99	Cedarlane	60	90	EB/AO	
48	NT	NT	NT	NT	NT	NT	NT	NT	18-Sep	18-Sep	Yes	No	NT	NT	NT	NT	NT	
51	0	0	2-8	0	0	0	8	0	17-Sep	19-Sep		Yes	95	Cedarlane	60	60	Fluoroquencher	
54	0%	0%	60%	0%					17-Sep	18-Sep		Yes	>95	Cedarlane	60	60	PI	
58	5%	5%	40%	5%	5%	5%	80%	5%	17-Sep	17-Sep	Yes	Yes	95	Cedarlane	60	90	Fluoroquencher	
62	1	1	1	1					17-Sep	17-Sep	Yes	Yes	99	Cedarlane	60	120	EB/AO	

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide  
AO - acridine orange  
PI - propidium iodide  
Hb - haemoglobin  
CFDA - carboxy-fluorescein diacetate

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014

DESPATCHED ON 26TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B62, B64; Cw9, Cw8; DR15, DR13; DQ6, -

Summary of Results					Summary of Results				
Total tested	19	19	18	19	15	15	14	15	
Positive	4	0	14	16	0	0	11	5	
Negative	15	19	4	3	15	15	3	10	
Not Tested	2	2	2	2	2	2	2	2	
% Positive	21.1%	0.0%	77.8%	84.2%	0.0%	0.0%	78.6%	33.3%	
% Negative	78.9%	100.0%	22.2%	15.8%	100.0%	100.0%	21.4%	66.7%	
<b>Consensus</b>	<b>Negative</b>	<b>Negative</b>	<b>Positive</b>	<b>Positive</b>	<b>Negative</b>	<b>Negative</b>	<b>Positive</b>	<b>Not Assessed</b>	
HLA Antibody (Defined By CDC)	DQ3	A32,B44,DR7	Bw6	B7,DR2					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	The blood was lysed - No cells recovered
11	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	
12	Weak Positive	Negative	Weak Positive	Weak Positive	Negative	Negative	Weak Positive	Negative	
14	Positive	Negative	Positive	Positive	Negative	Negative	Positive	Positive	
15	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Negative	Negative	Positive	Positive	Negative	Negative	Negative	Negative	
23	Negative	Negative	Positive	Positive					
24	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
25	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Negative	
28	Negative	Negative	Negative	Positive	Unsatisfactory	Unsatisfactory	Unsatisfactory	Unsatisfactory	
34	Positive	Negative	Positive	Positive	Negative	Negative	Positive	Negative	
38	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
39	NT	NT	NT	NT	NT	NT	NT	NT	
41	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
42	Negative	Negative	Weak Positive	Positive	Negative	Negative	Weak Positive	Negative	
45	Positive	Negative	Positive	Positive	Negative	Negative	Positive	Negative	
51	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Negative	
54	Negative	Negative	Positive	Positive					
58	Negative	Negative	Equivocal	Positive	Negative	Negative	Equivocal	Positive	
62	Negative	Negative	Negative	Positive					
									B-cell results not reported due to very low B-cell counts

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014

DESPATCHED ON 26TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
9	0	0	2	2	0	0	2	2	17-Sep	18-Sep	Yes	90	Cedarlane	30	30	AO/PI
11			2	2			2	2	18-Sep	19-Sep	Yes	90	Cedarlane	45	90	Fluoroquench
12	25%	2%	15%	20%	2%	2%	15%	2%	17-Sep	17-Sep	Yes	98	Cedarlane	30	60	EB/AO
14	2	0	6	8	0	0	6	6	17-Sep	17-Sep	Yes	90	Cedarlane	60	120	EB/AO
15			1				1		17-Sep	17-Sep	Yes	90	TCS Biosciences	60	60	EB/AO
19	NT	NT	NT	NT	NT	NT	NT	NT	17-Sep	18-Sep	NT	NT	NT	NT	NT	NT
20	1	1	3	3	1	1	1	1	17-Sep	18-Sep	Yes	90	Cedarlane	30	60	EB/AO
23	1	1	6	6					17-Sep	17-Sep	Yes	90	Cedarlane	40	40	EB/AO
24	20%	20%	40%	30%	20%	20%	30%	20%	17-Sep	18-Sep	Yes	80	Cedarlane	45	90	EB/AO
25	1	1	4	6	1	1	4	1	18-Sep	18-Sep	Yes	99	Cedarlane	45	60	Fluoroquench
28	1	1	1	4-6	0	0	0	0	17-Sep	17-Sep	Yes	85	Cedarlane	30	45	EB/AO
34	4	1	6	6	1	1	6	1	17-Sep	17-Sep	Yes	85	Cedarlane	30	90	EB/AO
38	1	1	1	1	1	1	1	1	17-Sep	17-Sep	Yes	95	Cedarlane	60	60	EB/AO
39	NT	NT	NT	NT	NT	NT	NT	NT	17-Sep	17-Sep	Yes	99	Cedarlane	45	90	EB/AO
41	2%	2%	2%	35%	5%	5%	5%	20%	17-Sep	17-Sep	Yes	98	Cedarlane	60	60	EB/AO
42			20%	40-60%				20%	17-Sep	18-Sep	Yes	95	TCS Biosciences	60	60	EB/AO
45	2	1	2-4	4-6	1	1	4	1	17-Sep	17-Sep	Yes	95	Cedarlane	30	75	EB/AO
51	0	0	1-4	2-4	0	0	4	0	17-Sep	19-Sep	Yes	95	Cedarlane	60	60	Fluoroquench
54	0%	0%	40%	40%					17-Sep	18-Sep	Yes	80	Cedarlane	60	60	PI
58	10%	10%		40%	10%	10%		50%	17-Sep	17-Sep	Yes	90	Cedarlane	60	90	Fluoroquench
62	1	1	1	4					17-Sep	17-Sep	Yes	90	Cedarlane	60	120	EB/AO

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide  
AO - acridine orange  
PI - propidium iodide  
Hb - haemoglobin  
CFDA - carboxy-fluorescein diacetate